e-learning
resources
Barcelona 2013
Monday, 09.09.2013
Sarcoidosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Relapse after discontinuation of infliximab in sarcoidosis patients can be predicted by PET-scan and sIL-2R
A. D. M. Vorselaars, A. Verwoerd, C. H. M. Van Moorsel, R. G. M. Keijsers, G. T. Rijkers, J. C. Grutters (Nieuwegein, Middelburg, Utrecht, Netherlands)
Source:
Annual Congress 2013 –Sarcoidosis
Session:
Sarcoidosis
Session type:
Oral Presentation
Number:
3063
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. D. M. Vorselaars, A. Verwoerd, C. H. M. Van Moorsel, R. G. M. Keijsers, G. T. Rijkers, J. C. Grutters (Nieuwegein, Middelburg, Utrecht, Netherlands). Relapse after discontinuation of infliximab in sarcoidosis patients can be predicted by PET-scan and sIL-2R. Eur Respir J 2013; 42: Suppl. 57, 3063
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Imaging of complicated pneumonia: what is new?
Emerging classes of drugs for the treatment of obstructive lung disease
Related content which might interest you:
Infliximab in patients with refractory sarcoidosis: Trough concentrations of infiximab
Source: International Congress 2015 – Clinical problems in acute and chronic lung diseases
Year: 2015
Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab
Source: International Congress 2016 – Sarcoidosis
Year: 2016
Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis
Source: Eur Respir J 2014; 43: 602-609
Year: 2013
Significant changes in monocyte subsets during infliximab therapy in severe sarcoidosis
Source: International Congress 2015 – Sarcoidosis: pathogenesis
Year: 2015
Sarcoidosis relapses in corticosteroid treated patients
Source: Annual Congress 2012 - Novelties in clinical management of thoracic diseases: from diaphragm to pleura
Year: 2012
Are there any predictors of MTX response in progressive pulmonary sarcoidosis?
Source: International Congress 2015 – Acute and chronic lung diseases: good clinical practice
Year: 2015
Unusual multisystemic relapse of sarcoidosis after corticosteroids withdrawal
Source: Annual Congress 2013 –Diffuse parenchymal lung disease III
Year: 2013
Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial
Source: Eur Respir J 2008; 31: 1189-1196
Year: 2008
Long-term treatment with infliximab in patients with sarcoidosis
Source: Annual Congress 2011 - Different profiles of sarcoidosis and other granulomatous disorders
Year: 2011
Corticosteroid treatment in sarcoidosis
Source: Eur Respir J 2006; 28: 627-636
Year: 2006
Infliximab: An effective rescue therapy in refractory extra-pulmonary sarcoidosis
Source: Annual Congress 2013 –Sarcoidosis and other granulomatosis
Year: 2013
How many patients require corticosteroid treatment in sarcoidosis? – Preliminary study
Source: International Congress 2014 – Sarcoidosis
Year: 2014
Methotrexate as a single agent for the treatment of patients with progressive pulmonary sarcoidosis
Source: International Congress 2015 – Sarcoidosis: clinical
Year: 2015
ACE and sIL2-R predict lung function improvement in sarcoidosis during methotrexate therapy
Source: Annual Congress 2013 –Sarcoidosis
Year: 2013
Rituximab for the treatment of chronic hypersensitivity pneumonitis
Source: International Congress 2015 – Interstitial lung diseases I
Year: 2015
ANCA associated vasculitis – Evaluation of diagnosis, treatment and outcome in a group of 68 patients
Source: International Congress 2014 – Clinical management of interstitial lung diseases and vasculitis
Year: 2014
Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis
Source: Eur Respir J 2015; 46: 175-185
Year: 2015
Methotrexate (MTX) as a single agent for treating chronic, progressive sarcoidosis
Source: International Congress 2014 – Sarcoidosis
Year: 2014
Safety of corticosteroid therapy in patients with pulmonary sarcoidosis
Source: International Congress 2017 – The many faces of sarcoidosis
Year: 2017
Anti-inflammatory therapy for sarcoidosis patients
Source: Annual Congress 2013 –Diffuse parenchymal lung disease III
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept